In the US, companies developing drugs for rare diseases, diseases with a prevalence of less than 200,000, can apply for designation as an Orphan Drug. This so-called ODD designation brings a number of benefits to the company - everything from tax credits to market exclusivity for 7 years to competitive pricing. Lars Frick, financial analyst, and Frank Sasinowski, US Regulatory expert, talk about the benefits of developing a drug with ODD and the history behind orphan drug designation.
- Күн бұрын
Abliva - Developing Drugs in Rare Diseases - Orphan Drug Designation
- Рет қаралды 222
Пікірлер